Skip to main contentAI and Advanced
/
SAILIFE · NSEBSE SENSEX74,781.76-0.16%BSE |
NIFTY 5023,398.1-0.34%NSE |
NIFTY BANK56,606.55+0.24%NSE |
NIFTY IT28,921.5+0.11%NSE |
NIFTY AUTO27,304.5-0.86%NSE |
NIFTY FMCG45,053.75-0.29%NSE |
NIFTY PHARMA26,532.4-0.09%NSE |
NIFTY 50022,866.5-0.37%NSE |
SA
NSE · Equity shares · Biotechnology & Drugs1.80 · 0.11%
Sai Life Sciences SAILIFE
NSE:INR 1,592.9
BSE:INR 1,594.3
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SAILIFE
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,591.1
Day rangeINR 1,571.4 — INR 1,616.1
52-week rangeINR 779.45 — INR 1,697
Volume11.70 L
Market cap30,046.91
P/E58.52
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,192.49
Net Income (INR Cr)348.91
P/E Ratio58.52
Book Value116.99
EPS16.71
Price/BV13.62Computed
Research path: Interpret Sai Life Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SAILIFESai Life Sciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,626.14 | 3,159.98 | 2,275.14 |
| Cash Equivalents | 110.87 | Not available | Not available |
| Other Liabilities Total | 32.32 | 23.41 | 20.38 |
| Long Term Debt | 20.5 | 0 | 277.73 |
| Common Stock Total | 21.18 | 20.84 | 18.05 |
| Other Current Assets Total | 624.11 | 136 | 16.71 |
| Total Assets | 3,626.14 | 3,159.98 | 2,275.14 |
| Current Portof LT Debt/Capital Leases | 140.33 | 187.69 | 100.39 |
| Total Equity | 2,483.69 | 2,128.35 | 975.14 |
| Long Term Investments | 3.51 | 1.94 | 1.87 |
| Retained Earnings(Accumulated Deficit) | 2,462.51 | 730.34 | 564.84 |
| Total Common Shares Outstanding | 21.18 | 20.84 | 20.8 |
| Property/Plant/Equipment Total-Gross | 270.45 | 2,196.59 | 1,748.71 |
| Tangible Book Valueper Share Common Eq | 116.99 | 101.6 | 46.22 |
| Total Liabilities | 1,142.45 | 1,031.62 | 1,299.99 |
| Total Debt | 288.45 | 352.38 | 928.14 |
| Short Term Investments | 150.96 | 281.13 | 161 |
| Cashand Short Term Investments | 261.83 | 372.25 | 184.66 |
| Total Receivables Net | 373.62 | 842.17 | 629.96 |
| Deferred Income Tax | 128.33 | 111.04 | 86.27 |
| Accounts Receivable-Trade Net | 373.62 | 761.5 | 567.83 |
| Property/Plant/Equipment Total-Net | 2,079.17 | 1,601.81 | 1,272.96 |
| Total Current Liabilities | 833.68 | 732.49 | 739.9 |
| Total Inventory | 150.97 | 129.26 | 92.57 |
| Accounts Payable | 285.34 | 322.51 | 199.41 |
| Other Currentliabilities Total | 408.01 | 142.76 | 64.15 |
| Total Long Term Debt | 148.12 | 164.69 | 453.45 |
| Intangibles Net | 6.12 | 10.86 | 13.77 |
| Other Long Term Assets Total | 123.58 | 28.46 | 18.28 |
| Note Receivable-Long Term | 3.24 | 12.4 | 23.14 |
| Total Current Assets | 1,410.53 | 1,504.51 | 945.11 |
| Capital Lease Obligations | 127.62 | 164.69 | 175.72 |
| Accumulated Depreciation Total | Not available | -594.78 | -475.75 |
| Accrued Expenses | Not available | 79.53 | 1.66 |
| Other Equity Total | Not available | 4 | 3.1 |
| Prepaid Expenses | Not available | 24.82 | 21.21 |
| Additional Paid-In Capital | Not available | 1,373.17 | 389.16 |
| Cash | Not available | 91.12 | 23.66 |
| Notes Payable/Short Term Debt | Not available | 0 | 374.3 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.38
Price to Sale Ratio13.70
Margins
Operating Margin 12m20.81
Net Profit Margin 12m15.91
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk32.74
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions4
Strong Sell count0
Sell count0
Hold count0
Buy count2
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 34.53%
- FII
- 19.65%
- MF
- 29.47%
- Other
- 16.35%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal StreetMarket news · 20 Jul 2026, 12:38 pm
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
Stock market today: Gift Nifty hints gap-down start; US-Iran news to gold, silver rates — eight stocks to buy or sellMarket news · 8 Jun 2026, 9:18 am
Stock market today: Experts recommend buying these eight shares today — Tata Technologies, Sai Life Sciences, Axis Bank, Eternal, Tata Steel, VA Tech Wabag, Diamond Power Infra, and Groww
Stock market today: Gift Nifty signals gap-up start; election results, India VIX to Q4 results — 7 stocks to buy or sellMarket news · 4 May 2026, 8:06 am
Stock market today: Experts recommend these eight stocks to buy today —Sona Blw Precision Forgings, Sai Life Sciences, Reliance, SAIL, GPPL, Thermax, and Tata Capital
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 17 March 2026Market news · 17 Mar 2026, 7:13 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Acutaas Chemicals, Aether Industries, Sai Life Sciences, Kirloskar Oil Engines, and CCL Products (India).
Buy or sell: Amid US-Iran war buzz, Vaishali Parekh recommends three stocks to buy today — 5 March 2026Market news · 5 Mar 2026, 9:16 am
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Hindustan Oil Exploration Company, MRPL, and Sai Life Sciences
Stock market today: Trade setup for Nifty 50, US-Iran war to gold, silver rates today; 8 stocks to buy or sell on MondayMarket news · 2 Mar 2026, 8:02 am
Stock market today: Experts have recommended eight stocks to buy today — Sai Life Sciences, R R Kabel, BEL, SAIL, HAL, OIL, Kalpataru Projects, and Godrej Agrovet
Corporate actions
Events
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results
ShareKeyX Community
Discussion and sentiment for Sai Life Sciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Sai Life Sciences Limited is an India-based company. The Company is a contract research, development, and manufacturing organization (CRDMO). It offers a range of tailor-made services for biotech firms or global pharma company requirements. Its services include integrated drug discovery services, drug metabolism and pharmacokinetics (DMPK), synthetic & medicinal chemistry, biology services, general toxicology, genotoxicity, and computational chemistry services. It also offers chemistry, manufacturing and controls (CMC) services which include route scouting, process familiarization, optimization & development, analytical method development & validation, process safety evaluation, stability studies, and early phase scale-up. Its discovery biology facility provides exploratory biology services to the expanding array of start-up and biotech companies in the Boston area and to companies in North America.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SAILIFE
- BSE Code
- 544306
Questions
Stock FAQ
What is the symbol and ISIN of Sai Life Sciences?
Sai Life Sciences has the symbol SAILIFE and ISIN - INE570L01029.
What is the current price of Sai Life Sciences?
Sai Life Sciences is currently trading at INR 1,592.90.
What are the year high and year low of Sai Life Sciences?
Sai Life Sciences has a year high of INR 1,697.00 and a year low of INR 779.45.
What is the market capitalization of Sai Life Sciences?
Sai Life Sciences has a market capitalization of INR 30,046.91 crore.
What is the P/E ratio of Sai Life Sciences?
Sai Life Sciences has a P/E ratio of 58.52.
What is the dividend yield of Sai Life Sciences?
Sai Life Sciences has a dividend yield of 0.00%.
How is the financial performance of Sai Life Sciences based on revenue, net income, and EPS?
Sai Life Sciences has revenue of INR 2,192.49 crore, net income of INR 348.91 crore, and EPS of INR 16.62.
What is the book value of Sai Life Sciences?
Sai Life Sciences has a book value of INR 116.99.
What is the debt-to-equity ratio of Sai Life Sciences?
Sai Life Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Sai Life Sciences?
Sai Life Sciences has a price-to-book ratio of 13.62 and a price-to-sales ratio of 13.70.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.